Mylan gets OK for generic Femara

PITTSBURGH — Mylan has launched a generic treatment for breast cancer, the drug maker said Monday.

Mylan announced the launch of letrozole tablets in the 2.5-mg strength, an adjuvant treatment for postmenopausal women with hormone receptor-positive early-stage breast cancer.

The drug is the first generic version of Novartis’ Femara, which had sales of about $682 million in 2010, according to IMS Health.

Recommended stories

Login or Register to post a comment.